Trust the Original to help you turn it off.
|
|
- Ashlie Pitts
- 5 years ago
- Views:
Transcription
1 Trust the Original to help you turn it off.
2 Trust the Original to help you turn it off.
3 Trust the Original to help you turn it off.
4 Trust the Original to help you turn it off.
5 Trust the Original to help you turn it off.
6 Trust the Original to help you turn it off.
7 ,
8 , Trust the Original Levocetrizine Original Research Molecule The only levocetrizine brand used in maximum clinical trials Say NO to allergy. Say YES to the original. Montelukast International Standard Certificate of Suitability given # by EDQM # EDQM: European Directorate for the Quality of Medicines
9 , Trust the Original Say NO to allergy. Say YES to the original. Levocetrizine Montelukast
10 , Trust the Original Say NO to allergy. Say YES to the original. Levocetrizine Montelukast
11 , Trust the Original Say NO to allergy. Say YES to the original.
12 , Trust the Original Say NO to allergy. Say YES to the original. IRB* TECHNOLOGY * IRB: Immediate Release Bi-Layer Technology
13 Say NO to allergy. Say YES to the original. 1,2,3 For faster, longer and 24 hours efficacy, 1. J Investig Allergol Clin Immunol 2006; Vol. 16, Supplement 1: Comparative pharmacology of the H1 antihistamines. A del Cuvillo, J Mullol, J Bartra 2. British Journal of Clinical Pharmacology DOI: /j Allergy Asthma Proc Jul-Aug:30(4);366-76
14 , Say NO to allergy. Say YES to the original.
15 Say NO to allergy. Say YES to the original., Also Available
16 Name of Medicinal Product: Xyzal M tablets. Qualitative and Quantitative Composition: Each tablet contains: Levocetirizine dihydrochloride IP 5 mg and Montelukast sodium equivalent to Montelukast 10 mg. Pharmaceutical Form: White and light pink coloured, round, bilayered, flat faced, bevelled edge, noncoated tablet scored on one side and plain on the other side. Therapeutic Indications: For the treatment of allergic rhinitis in adults only. Posology and Method of Administration: The usual dose is Montelukast sodium 10mg and Levocetirizine dihydrochloride 5 mg given once a daily orally. Contra-Indications: Levocetirizine: The use of Levocetirizine is contra indicated in patients with known hypersensitivity to Levocetirizine or any other ingredients of Levocetirizine, or to cetirizine. The observed reactions range from urticaria to anaphylaxis. Levocetirizine is also contraindicated in patients with end-stage renal disease [CLCR<mL/ min] and patients undergoing haemodialysis. Montelukast: Hypersensitivity to any component of this product. Special Warnings and Precautions: Levocetirizine: Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness and motor coordination such as driving or operating machinery whe taking Levocetirizine. Avoid concurrent use of alcohol or other central nervous system depressants with Levocetirizine. Montelukast: Montelukast should not be used as monotherapy for the treatment and management of exercise induced bronchospasm. Patients who have exacerbations of asthma after exercise should continue to use their usual regimen of inhaled (beta)-agonist prophylaxis and have available for rescue a short acting inhaled (beta)-agonist. Patients with known aspirin sensitivity should continue avoidance of aspirin or non-steroidal anti-inflammatory agents while taking Montelukast. In Eosinophilic Conditions in rare cases, patients on therapy with Montelukast may present with systemic eosinophilia,sometimes presentingwith clinical features fo vasculitis consistent with Churg Strauss syndrome, a condition, which is often treated with systemic corticosteroid therapy. Undesirable Effects: The possible side effects of Levocetirizine are somnolence, nasopharyngitis, fatigue, dry mouth, and pharyngitis, and most wetre mild to moderate in intensity. Others like pyrexia, cough and epistaxis were also reported. The possible side effects of Montelukast are asthenia/fatigue, fever, abdominal pain, trauma, dyspepsia, gastroenteritis, infectious dental pain, dizziness, headache, nasal congestion, cough, influenza, rash, increase in ALTand AST levels, pyuria. Overdose: Levocetirizine: Symptoms of overdose may include drowsiness in adults and initially agitation and restlesness, followed by drowsiness in childrens. Montelukast: There have been reports of acute overdosage in postmarketing experience and clinical studies with Montelukast. These include reports in adults and children with a dose as higher as 1000mg. The clinical and laboratory findings observed were consistent with the safety profile in adults and paediatric patients. The most frequently occuring adverse experiences were consistent with safety profile of Montelukast and included abdominal pain, somnolence, thirst, headache, vomiting and psychomotor hyperactivity. Keep out of reach of children. Please refer to the full prescribing information before usage. Xyzal M Tablets Abbreviated version th Aug2013 GGI-CO-A2-GR-XM VA-F17-150
Composition: Each tablet contain. Levocetirizine. Each 5ml contains. Montelukast. Pharmacokinetic properties:
Composition: Each tablet contain Montelukast Levocetirizine 10mg 5mg Each 5ml contains Montelukast Levocetirizine 4mg 2.5mg Pharmacokinetic properties: Peak plasma concentrations of montelukast are achieved
More informationMonocast Description Indications
Monocast Tablet Description The active ingredient of Monocast tablet is Montelukast Sodium INN. Montelukast is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl
More informationMTnL Tablet/ MTnL Kid Tablet Montelukast & Levocetirizine dihydrochloride
MTnL Tablet/ MTnL Kid Tablet Montelukast & Levocetirizine dihydrochloride COMPOSITION MTnL Tablets Each film-coated tablet contains: Montelukast sodium equivalent to montelukast Levocetirizine dihydrochloride
More informationLevocetirizine dihydrochloride
INSERT TEXT UAP Levocetirizine dihydrochloride Allerzet 5 mg Tablet Antihistamine FORMULATION Each film-coated tablet contains: Levocetirizine dihydrochloride.. 5 mg PRODUCT DESCRIPTION Levocetirine 5
More informationLocal Omalizumab Treatment Protocol (For children 6 to <12 years of age)
Local Omalizumab Treatment Protocol (For children 6 to
More informationMONTAIR LC & MONTAIR LC KID DT / Syrup (Montelukast sodium + Levocetirizine dihydrochloride )
Published on: 18 Dec 2015 MONTAIR LC & MONTAIR LC KID DT / Syrup (Montelukast sodium + Levocetirizine dihydrochloride ) Composition MONTAIR LC Tablets Each uncoated bilayered tablet contains: Montelukast
More informationCetirizine Proposed Core Safety Profile
Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function
More informationSUMMARY OF PRODUCT CHARACTERISTICS
MUTUAL RECOGNITION PROCEDURE Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT, syrup 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of syrup contains 1 mg loratadine.
More informationPATIENT INFORMATION LEAFLET SINTAIR RANGE
SCHEDULING STATUS: S3 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: SINTAIR 4 mg (chewable tablets) SINTAIR 5 mg (chewable tablets) SINTAIR 10 mg (tablets) Please read this leaflet carefully before
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. THORDEL 4 mg chewable tablets montelukast
PACKAGE LEAFLET: INFORMATION FOR THE USER THORDEL 4 mg chewable tablets montelukast 1 PACKAGE LEAFLET: INFORMATION FOR THE USER THORDEL 4 mg chewable tablets montelukast Read all of this leaflet carefully
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET VERGO 16 1. Product Name Vergo 16, 16 mg, tablet. 2. Qualitative and Quantitative Composition Each tablet contains 16 mg of betahistine dihydrochloride. For the full list of excipients,
More informationPACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP
PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP Brand or Product Name [Product name] Tablet 2mg [Product name] Tablet 4mg [Product name] Syrup 2mg/5ml Name and Strength of Active Substance(s)
More informationEach 5ml of Sinarest LP New Syrup contains: Phenylephrine
Composition: Each 5ml of Sinarest LP New Syrup contains: Paracetamol Phenylephrine Levocetrizine 250mg 5mg 1.25mg Pharmacokinetic properties: Paracetamol is readily absorbed from the gastrointestinal tract
More informationSINGULAIR JUNIOR 5mg chewable tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER SINGULAIR JUNIOR 5mg chewable tablets MONTELUKAST This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,
More informationPage 1 of 9. Revised: 09/2012 FULL PRESCRIBING INFORMATION: CONTENTS *
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use XYZAL safely and effectively. See full prescribing information for XYZAL. XYZAL (levocetirizine dihydrochloride)
More informationM0BCore Safety Profile
M0BCore Safety Profile Active substance: Aciclovir Pharmaceutical form(s)/strength: Tablets 200, 400 or 800 mg Dispersible tablets 200, 400 or 800 mg Oral suspensions 200 mg or 400 mg per 5 ml. Freeze
More informationMigraleve, Migraleve Pink and Migraleve Yellow Product Information
Migraleve, Migraleve Pink and Migraleve Yellow Product Information Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Comfora 595 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains: glucosamine sulphate
More informationAgreed Core Safety Profile for Budesonide nasal spray suspension and Budesonide nasal powder
CSP Drug Budesonide Substance Date 13 Oct 2011 rev 11Nov Supersedes 18 Aug 2011 Agreed Core Safety Profile for DK/H/PSUR/0041/001 TABLE OF CONTENTS PAGE TITLE PAGE... 1 TABLE OF CONTENTS... 2 Introduction...
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ebateva 10 mg Orodispersible Tablets Ebateva 20 mg Orodispersible Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One orodispersible
More informationNew Zealand Data Sheet
New Zealand Data Sheet Name of Medicine SINGULAIR montelukast sodium 10 mg tablet 5 mg chewable tablet 4 mg chewable tablet Presentation 10 mg tablet: A beige rounded square film-coated tablet engraved
More informationAUSTRALIAN PRODUCT INFORMATION APO-BETAHISTINE (BETAHISTINE DIHYDROCHLORIDE) 2 AND 3 QUALITATIVE AND QUANTITATIVE COMPOSITION AND PHARMACEUTICAL FORM
AUSTRALIAN PRODUCT INFORMATION APO-BETAHISTINE (BETAHISTINE DIHYDROCHLORIDE) 1 NAME OF THE MEDICINE Betahistine dihydrochloride. 2 AND 3 QUALITATIVE AND QUANTITATIVE COMPOSITION AND PHARMACEUTICAL FORM
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fexofenadine Cipla 120 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 120 mg fexofenadine
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fexofenadine hydrochloride 180 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film coated tablet contains 180mg
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use MONTELUKAST SODIUM TABLETS safely and effectively. See full prescribing information for MONTELUKAST
More informationPackage leaflet: Information for the user. Cinfalair 4 mg chewable tablets montelukast
Package leaflet: Information for the user Cinfalair 4 mg chewable tablets montelukast Read all of this leaflet carefully before you give this medicine to your child because it contains important information.
More informationPRODUCT INFORMATION LUKAIR. (montelukast sodium) Tablets NAME OF THE MEDICINE
PRODUCT INFORMATION LUKAIR (montelukast sodium) Tablets NAME OF THE MEDICINE Montelukast sodium LUKAIR, (montelukast sodium) is described chemically as [R-(E)]-1-[[[1-[3-[2-(7-chloro-2- quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]
More informationPackage leaflet: Information for the user. Cinfalair Paediatric 4 mg Granules montelukast
Package leaflet: Information for the user Cinfalair Paediatric 4 mg Granules montelukast Read all of this leaflet carefully before you give this medicine to your child because it contains important information.
More informationXYZAL 5 MG FILM-COATED TABLET
XYZAL 5 MG FILM-COATED TABLET Levocetirizine dihydrochloride Read all of this leaflet carefully because it contains important information for you. This medicine is available without prescription. However,
More informationPackage leaflet: Information for the user. Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride
Package leaflet: Information for the user Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationBody weight more than 30kg : 10ml (10mg) of the syrup once daily.
1. Name of the medicinal product Clarityn Allergy 1mg/ml Syrup 2. Qualitative and quantitative composition Each ml of syrup contains 1mg loratadine. Excipients with known effect. The quantity of sucrose
More informationSalapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup.
Salapin Salbutamol Syrup 2mg/5mL Qualitative and quantitative composition Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup. Clinical particulars Therapeutic
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Montelukast 4 mg chewable Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One chewable tablet contains montelukast sodium, which is
More informationPackage leaflet: Information for the user Montelukast 10 mg film-coated tablets Montelukast
Package leaflet: Information for the user Montelukast 10 mg film-coated tablets Montelukast Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPATIENT INFORMATION LEAFLET FOR TEXA 10 mg TABLETS AND TEXA SYRUP PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM:
SCHEDULING STATUS: S2 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: TEXA 10 mg (tablets) TEXA SYRUP (syrup) Read this entire leaflet carefully before you start taking TEXA. Keep this leaflet. You
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Betahistine dihydrochloride 8 mg tablets Betahistine dihydrochloride 16 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Betahistine
More informationBOLSTRAN Injection (Omalizumab)
Published on: 27 Feb 2017 BOLSTRAN Injection (Omalizumab) Composition Active Substance Omalizumab is a humanized monoclonal antibody manufactured from a mammalian cell line. One vial of BOLSTRAN 150 mg
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Cinfalair 4 mg chewable tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Cinfalair 4 mg chewable tablets Read all of this leaflet carefully before your child starts taking this medicine. Keep this leaflet. You may need to read it again.
More informationFLOMIST Aqueous Nasal Spray (Fluticasone propionate)
Published on: 10 Jul 2014 FLOMIST Aqueous Nasal Spray (Fluticasone propionate) Composition FLOMIST Aqueous Nasal Spray Each spray delivers: Fluticasone Propionate BP...50 mcg Fluticasone Propionate BP...
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER Cinfalair 10 mg film-coated tablets Montelukast
PACKAGE LEAFLET: INFORMATION FOR THE USER Cinfalair 10 mg film-coated tablets Montelukast Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. THORDEL 10 mg film-coated tablets montelukast
PACKAGE LEAFLET: INFORMATION FOR THE USER THORDEL 10 mg film-coated tablets montelukast Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPackage leaflet: Information for the user. Cinfalair10 mg film-coated tablets montelukast
Package leaflet: Information for the user Cinfalair10 mg film-coated tablets montelukast Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationTIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain
TIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain Second Low-Dose SoluMatrix NSAID from Iroko Now Available by Prescription PHILADELPHIA, June 29, 2015 Iroko Pharmaceuticals, LLC,
More information4 mg Chewable tablet: One chewable tablet contains montelukast sodium, which is equivalent to 4 mg montelukast.
SUMMARY OF PRODUCT CHARACTERISTICS 1. TRADE NAME OF THE MEDICINAL PRODUCT Montelukast 4 mg Chewable tablets Montelukast 5 mg Chewable tablets Montelukast 10 mg Film-coated tablets 2. QUALITATIVE AND QUANTITATIVE
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Betahistine dihydrochloride 8 mg tablets Betahistine dihydrochloride 16 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Betahistine
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Telfast 120 mg film-coated tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 120 mg of fexofenadine hydrochloride,
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT {To be completed nationally} 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 mg tablets: each tablet contains 1 mg granisetron (as hydrochloride).
More informationSUMMARY OF PRODUCT CHARACTERISTICS. One film-coated tablet contains 10 mg of cetirizine dihydrochloride.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cetirizin STADA 10 mg, film-coated tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains 10 mg of cetirizine
More informationPackage leaflet: Information for the patient
Xyzal 5 mg/ml oral drops, solution Page 1 of 5 Package leaflet: Information for the patient Xyzal 5 mg/ml oral drops, solution For adults and children aged 2 years and above Levocetirizine dihydrochloride
More informationSINGULAIR 10mg film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER SINGULAIR 10mg film-coated tablets MONTELUKAST This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,
More informationPackage leaflet: Information for the patient
Page 1 of 5 Package leaflet: Information for the patient Xyzal 5 mg/ml oral drops, solution For adults and children aged 2 years and above Levocetirizine dihydrochloride Read all of this leaflet carefully
More informationPRODUCT INFORMATION SINGULAIR. (montelukast sodium) Tablets and Oral Granules NAME OF THE MEDICINE
PRODUCT INFORMATION SINGULAIR (montelukast sodium) Tablets and Oral Granules NAME OF THE MEDICINE Montelukast sodium SINGULAIR, (montelukast sodium) is described chemically as [R-(E)]-1-[[[1-[3-[2-(7-
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Zaditen 0.25 mg/ml, eye drops, solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains 0.345 mg ketotifen fumarate corresponding
More informationPatient Information Montelukast Sodium Tablets and Montelukast Sodium Chewable Tablets
Patient Information Montelukast Sodium Tablets and Montelukast Sodium Chewable Tablets Read the Patient Information Leaflet that comes with montelukast sodium before you start taking it and each time you
More informationNEW ZEALAND DATA SHEET APO-MONTELUKAST
NEW ZEALAND DATA SHEET APO-MONTELUKAST 1 APO-MONTELUKAST (10mg tablets) APO-MONTELUKAST (4mg & 5mg chewable tablets) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Montelukast as sodium 10mg Montelukast as
More informationLevocetirizine dihydrochloride
Levocetirizine dihydrochloride Xyzal Oral Preparations PRODUCT DESCRIPTION Each film-coated tablet of Levocetirizine dihydrochloride (Xyzal ) contains 5 mg of levocetirizine. Each ml of Levocetirizine
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% Date of FAR:
Core Safety Profile Active substance: Carteolol Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% P - RMS: SK/H/PSUR/0002/002 Date of FAR: 16.03.2012 4.1 THERAPEUTIC INDICATIONS Ocular hypertension
More informationPharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS:
0BCore Safety Profile Active substance: Betaxolol eyedrops Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS: HU/H/PSUR/0010/002 Date of FAR: 20.03.2013 4.2 Posology
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Dry Powder Inhaler, Nebuliser Suspension, pressurised Metered Dose Inhaler (pmdi)
Core Safety Profile Active substance: Budesonide Pharmaceutical form(s)/strength: Dry Powder Inhaler, Nebuliser Suspension, pressurised Metered Dose Inhaler (pmdi) P - RMS: DK/H/PSUR/0041/001 Date of FAR:
More informationDrug Effectiveness Review Project Literature Scan Summary. Month/Year of Review: January 2015 Date of Last Review: January 2013
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301 1079 Phone 503 947 5220 Fax 503 947 1119 Copyright 2012 Oregon State University. All Rights
More informationPackage Insert. Levasma Suspension. Product Summary. 1. Name of the medicinal product
Package Insert Levasma Suspension Product Summary 1. Name of the medicinal product Levasma suspension 2. Qualitative and quantitative composition Each 5 ml contains: Levocetirizine Dihydrochloride IP 2.5mg
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Aerius 5 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5 mg desloratadine. For a
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) Date of FAR:
Core Safety Profile Active substance: Doxazosin Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) P - RMS: DK/H/PSUR/0004/002 Date of FAR: 12.12.2011 4.3 Contraindications
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Each film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Montelukast Actavis 10 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains montelukast
More informationNEW ZEALAND DATA SHEET ACUPAN TM. 3. PHARMACEUTICAL FORM White, round, biconvex, film-coated tablets (7 mm diameter) engraved APN on one face.
1. PRODUCT NAME ACUPAN 30 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains nefopam hydrochloride 30 mg. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM
More informationScottish Medicines Consortium
Scottish Medicines Consortium montelukast 10mg tablets (Singulair ) No. (185/05) Merck, Sharp & Dohme Ltd (MSD) New indication: for asthmatic patients in whom montelukast is indicated in asthma, montelukast
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER ZIRPINE 10mg TABLETS Cetirizine dihydrochloride
PACKAGE LEAFLET: INFORMATION FOR THE USER ZIRPINE 10mg TABLETS Cetirizine dihydrochloride Read all of this leaflet carefully because it contains important information for you. This medicine is available
More informationALLERGIC RHINOSINUSITIS. Sirisha A Post graduate Dept of Pharmacology Kamineni Institute of Medical Sciences
ALLERGIC RHINOSINUSITIS Sirisha A Post graduate Dept of Pharmacology Kamineni Institute of Medical Sciences OVERVIEW Pathophysiology Goals of therapy Approaches to therapy Antihistaminics Corticosteroids
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cetirizin Mylan 10 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 10 mg of cetirizine
More informationAntiallergics and drugs used in anaphylaxis
Antiallergics and drugs used in anaphylaxis Antiallergics and drugs used in anaphylaxis The H 1 -receptor antagonists are generally referred to as antihistamines. They inhibit the wheal, pruritus, sneezing
More informationIPRAVENT Rotacaps (Ipratropium bromide)
Published on: 10 Jul 2014 IPRAVENT Rotacaps (Ipratropium bromide) Composition IPRAVENT Rotacaps Each capsule contains: Ipratropium Bromide BP, equivalent to Ipratropium Bromide (anhydrous) 40 mcg Excipient..q.s.
More informationPackage leaflet: Information for the patient. Cetirizin Sandoz 10 mg film-coated tablets. cetirizine dihydrochloride
Package leaflet: Information for the patient Cetirizin Sandoz 10 mg film-coated tablets cetirizine dihydrochloride [For medicine available only on prescription:] Read all of this leaflet carefully before
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Aerius 5 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5 mg desloratadine. Excipient(s)
More information1. What Betahistine dihydrochloride tablets is and what it is used for
Package leaflet: Information for the user Betahistine dihydrochloride 8 mg tablets Betahistine dihydrochloride 16 mg tablets Betahistine dihydrochloride Read all of this leaflet carefully before you start
More informationpatient group direction
NAPROXEN v01 1/10 NAPROXEN PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)
More informationTranslated from Latvian Approved by SAM on
Translated from Latvian SAM on 29.07.2010 1. NAME OF THE MEDICINAL PRODUCT FENKAROL 10 mg Tablets FENKAROL 25 mg Tablets FENKAROL 50 mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance
More informationIroko Pharmaceuticals Gains Additional Patents for ZORVOLEX and TIVORBEX TM
Iroko Pharmaceuticals Gains Additional Patents for ZORVOLEX and TIVORBEX TM PHILADELPHIA, April 8, 2015 Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the
More informationThe proposal is to add text/statements in red and to delete text/statements with strikethrough: POLICY
Omalizumab DESCRIPTION Omalizumab is a recombinant DNA-derived humanized IgG1κ monoclonal antibody which selectively binds to immunoglobulin E (IgE). High serum levels of IgE are found in individuals with
More informationPharmaceutical form(s)/strength: Capsules, 200mg, 400mg, Oral suspensions, 90mg/5ml, 180mg/5ml, 36 mg/ml SI/H/PSUR/0002/002 Date of FAR:
0BCore Safety Profile Active substance: Ceftibuten Pharmaceutical form(s)/strength: Capsules, 200mg, 400mg, Oral suspensions, 90mg/5ml, 180mg/5ml, 36 mg/ml P-RMS: SI/H/PSUR/0002/002 Date of FAR: 14.02.2013
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Rinozal 5 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 5 mg levocetirizine dihydrochloride
More informationFURAMIST Nasal Spray (Fluticasone furoate )
Published on: 21 Jan 2016 FURAMIST Nasal Spray (Fluticasone furoate ) Composition Each spray contains: Fluticasone furoate 27.5 mcg Dosage Form Aqueous intranasal spray Pharmacology Pharmacodynamics Fluticasone
More informationChildren Enteric coated tablet : 1-3 mg/kg per day in divided doses.
Ultrafen Tablet/SR Tablet/Suppository/Gel Description Ultrafen is a preparation of Diclofenac is a non-steroidal antiinflammatory agent with marked analgesic, anti-inflammatory and antipyretic properties.
More informationCLINICAL PHARMACOLOGY
robaxin / robaxin -7 50 (methocarbamol tablets, USP) Rx Only DESCRIPT ION robaxin /robaxin -750 (methocarbamol tablets, USP), a carbamate derivative of guaifenesin, is a central nervous system (CNS) depressant
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory LONGCET. Levocetirizine Dihydrochloride Tablets IP 5 mg
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory LONGCET Levocetirizine Dihydrochloride Tablets IP 5 mg QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet
More informationCoverage Criteria: Express Scripts, Inc. monograph dated 03/03/2010
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Xolair (omalizumab) Commercial HMO/PPO/CDHP HMO/PPO/CDHP: Rx
More informationxx Xolair 150 MG SOLR (GENENTECH)
Omalizumab NDC CODE(S) 50242-0040-xx Xolair 150 MG SOLR (GENENTECH) DESCRIPTION Omalizumab is a recombinant DNA-derived humanized IgG1κ monoclonal antibody which selectively binds to immunoglobulin E (IgE).
More informationSINGULAIR (Montelukast Sodium) Tablets, Chewable Tablets, and Oral Granules
SINGULAIR (montelukast sodium) tablets, chewable tablets, and oral granules HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SINGULAIR safely and
More informationXOLAIR (omalizumab) Prior Authorization
MP9309 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below May only be prescribed by Allergy, Pulmonary, Immunology or Dermatology specialists
More informationProduktinformationen för Bentifen, 0,25 mg/ml, Ögondroppar, lösning, endosbehållare, MTnr 16252, gäller vid det tillfälle då läkemedlet godkändes.
Produktinformationen för Bentifen, 0,25 mg/ml, Ögondroppar, lösning, endosbehållare, MTnr 16252, gäller vid det tillfälle då läkemedlet godkändes. Informationen kommer inte att uppdateras eftersom läkemedlet
More informationMerck Sharp & Dhome 1. NAME OF THE MEDICINAL PRODUCT
SINGULAIR 10 mg film-coated tablets Merck Sharp & Dhome 1. NAME OF THE MEDICINAL PRODUCT SINGULAIR 10 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Unichem Allergy Relief Antihistamine Tablets Moss Pharmacy Allergy Relief Antihistamine Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Montelukast Paediatric 4mg Chewable Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each chewable tablet contains 4.16 mg montelukast
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPROFESSIONAL INFORMATION
SCHEDULING STATUS: S1 PROPRIETARY NAME AND DOSAGE FORM: Aleve Tablets COMPOSITION: Each tablet contains naproxen sodium 220 mg (equivalent to 200 mg naproxen) CATEGORY AND CLASS: A / 2.7 Antipyretic or
More informationGreater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma
Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma Non-pharmacological options for ALL patients, consider at ALL stages Make sure diagnosis
More information